Literature DB >> 19550417

Fatty acids, IL6, and TNFalpha polymorphisms: an example of nutrigenetics in Crohn's disease.

Catarina Sousa Guerreiro1, Paula Ferreira, Lourdes Tavares, Paula Moura Santos, Manuela Neves, Miguel Brito, Marília Cravo.   

Abstract

OBJECTIVES: The aim of this work was to study the interaction between genetic polymorphisms (single-nucleotide polymorphisms, SNPs) of pro- and anti-inflammatory cytokines and fat intake on the risk of developing Crohn's disease (CD) or modifying disease activity.
METHODS: Seven SNPs in interleukin 1 (IL1), tumor necrosis factor alpha (TNFalpha), lymphotoxin alpha (LTalpha), and IL6 genes were analyzed in 116 controls and 99 patients with CD. The type of fat intake was evaluated, and the interaction between SNPs and dietary fat in modulating disease activity was analyzed.
RESULTS: Individuals who were homozygous for the IL6-174G/C polymorphism had a six-fold higher risk for CD (odds ratio (OR)=6.1; 95% confidence interval (95% CI)=1.9-19.4), whereas the TT genotype on the TNFalpha-857C/T polymorphism was associated with more active disease (OR=10.4; 95% CI=1.1-94.1). A high intake of total, saturated, and monounsaturated fats, as well as a higher ratio of n-6/n-3 polyunsaturated fatty acid (PUFA), was associated with a more active phenotype (P<0.05). Furthermore, there was an interaction between dietary fat intake and SNPs, with a high intake of saturated and monounsaturated fats being associated with active disease, mainly in patients carrying the variant alleles of the 857 TNFalpha polymorphism (OR=6.0, 95% CI=1.4-26.2; OR=5.17; 95% CI=1.4-19.2, respectively) and the 174 IL6 polymorphism (OR=2.95; 95% CI=1.0-9.1; OR=3.21; 95% CI=1.0-10.4, respectively). Finally, low intake of n-3 PUFA and high n-6/n-3 PUFA ratio in patients with the TNFalpha 857 polymorphism were associated with higher disease activity (OR=3.6; 95% CI=1.0-13.0; OR=5.92; 95% CI=1.3-26.5, respectively).
CONCLUSIONS: These results show that different types of fat may interact with cytokine genotype, modulating disease activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19550417     DOI: 10.1038/ajg.2009.313

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  16 in total

1.  A meta-analysis on the association between three promoter variants of TNF-α and Crohn's disease.

Authors:  Cui Xie; Xiao Feng Liu; Mao Sheng Yang
Journal:  Mol Biol Rep       Date:  2011-06-03       Impact factor: 2.316

Review 2.  Dietary management of IBD--insights and advice.

Authors:  Emma P Halmos; Peter R Gibson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-03       Impact factor: 46.802

Review 3.  Interactions between dietary n-3 fatty acids and genetic variants and risk of disease.

Authors:  Dolores Corella; José M Ordovás
Journal:  Br J Nutr       Date:  2012-06       Impact factor: 3.718

Review 4.  Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature.

Authors:  Thomas D Martin; Simon S M Chan; Andrew R Hart
Journal:  Dig Dis Sci       Date:  2014-11-19       Impact factor: 3.199

5.  Predictors of response to enteral nutrition in abdominal enterocutaneous fistula patients with Crohn's disease.

Authors:  D Yan; J Ren; G Wang; S Liu; J Li
Journal:  Eur J Clin Nutr       Date:  2014-03-12       Impact factor: 4.016

6.  Marked elevations in pro-inflammatory polyunsaturated fatty acid metabolites in females with irritable bowel syndrome.

Authors:  Gerard Clarke; Peter Fitzgerald; Alan A Hennessy; Eugene M Cassidy; Eamonn M M Quigley; Paul Ross; Catherine Stanton; John F Cryan; Timothy G Dinan
Journal:  J Lipid Res       Date:  2009-11-11       Impact factor: 5.922

Review 7.  Interleukin and interleukin receptor gene polymorphisms in inflammatory bowel diseases susceptibility.

Authors:  Lili Magyari; Erzsebet Kovesdi; Patricia Sarlos; Andras Javorhazy; Katalin Sumegi; Bela Melegh
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

Review 8.  Diet and nutrition in the management of inflammatory bowel disease.

Authors:  Pabitra Sahu; Saurabh Kedia; Vineet Ahuja; Rakesh K Tandon
Journal:  Indian J Gastroenterol       Date:  2021-05-26

9.  IL6 genetic variants haplotype is associated with susceptibility and disease activity but not with therapy response in patients with inflammatory bowel disease.

Authors:  Beatriz Piantoni Gonçalves; Tamires Flauzino; Cláudia Junko Inoue; Jaqueline Costa Castardo de Paula; Talita Cristina Galvão; Camila Cataldi de Alcantara; Paula Kikuchi Miyazaki; Lucilene Rosa; Silva Westmore; Marcell Alysson Batisti Lozovoy; Edna Maria Vissoci Reiche; Andréa Name Colado Simão
Journal:  Int J Colorectal Dis       Date:  2020-10-12       Impact factor: 2.571

10.  Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.

Authors:  Katie Stone; Emily Woods; Susann M Szmania; Owen W Stephens; Tarun K Garg; Bart Barlogie; John D Shaughnessy; Brett Hall; Manjula Reddy; Antje Hoering; Emily Hansen; Frits van Rhee
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.